The March 1, 2017 article by Naidoo et al entitled “Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy” (J Clin Oncol 35:709-717, 2017) was published with errors.
The manuscript should have stated that Dr. Georgina Long and Dr. Matthew Hellmann contributed equally to the manuscript.
The full name of CTLA-4 is written out incorrectly as anti–cytotoxic T-cell lymphocyte-4 mAb in the methods and conclusion sections of the abstract, in the introduction and in the legend for Figure 2. The sentences with the correct full name, anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb, should have read as follows:
Abstract/Methods:
“Patients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb were identified…”
Abstract/Conclusions:
“It is more common when anti–PD-1/PD-L1 mAbs are combined with anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb”
Introductions:
“… with durvalumab (PD-L1 mAb) and tremelimumab (cytotoxic T-cell lymphocyte associated antigen-4 [CTLA-4] mAb.”
Legend of figure 2:
“versus in combination with anti–cytotoxic T-cell lymphocyte associated antigen-4 monoclonal antibody.
The online version has been corrected in departure from the print. The authors apologize for the errors.